Product Information
URO-PAIN 99.5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1840 per EA under NDC 57237033021. Its NADAC has been published 118 times since Jul 3, 2024.
Strength
99.5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
57237033021
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PHENAZOPYRIDINE HYDROCHLORIDEApproval Type
Unapproved
On Market Since
12/6/2023
Price Statistics
The NADAC for URO-PAIN 99.5 MG TABLET has been published 118 times since Jul 3, 2024, and over the history we have for it it has declined 2.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1840 per EA |
|---|---|
| All-time high | $0.2052 (Sep 11, 2024) |
| All-time low | $0.1730 (Sep 17, 2025) |
| 52-week high | $0.1971 |
| 52-week low | $0.1730 |
| Median price | $0.1822 |
| Average price | $0.1835 |
| Largest weekly change | +16.1% (Aug 21, 2024) |
| Weeks tracked | 118 |
| Tracking since | Jul 3, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Phenazopyridine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of URO-PAIN 99.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for URO-PAIN 99.5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.1840 per EA (NDC 57237033021), effective Sep 30, 2026.
How has the price of URO-PAIN 99.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for URO-PAIN 99.5 MG TABLET has declined 2.6%. It has been tracked across 118 weekly CMS publications since Jul 3, 2024.
What are the highest and lowest recorded NADAC prices for URO-PAIN 99.5 MG TABLET?
Since Jul 3, 2024, the NADAC for URO-PAIN 99.5 MG TABLET has ranged from a low of $0.1730 (Sep 17, 2025) to a high of $0.2052 (Sep 11, 2024), with a median of $0.1822 per EA.
Are there cheaper alternatives to URO-PAIN 99.5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as URO-PAIN 99.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures URO-PAIN 99.5 MG TABLET?
URO-PAIN 99.5 MG TABLET (NDC 57237033021) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.